Eli Lilly and Co (LLY)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+41% over the past year+3
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 46% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is M&A, centered on Lilly's up-to-$1.5 billion acquisition of Calytrix Bio and its preclinical antibody assets. Continuation likelihood over the next few weeks is moderate (~40–50%), since deal news tends to fade quickly while the broader GLP-1 narrative remains a persistent backdrop. Informational only — not financial advice.
- Eli Lilly to Acquire Calytrix Bio in Up to $1.5 Billion DealYahoo · 2026-11-16
- Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-HeadYahoo · 2026-11-16
- Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical AntibodyYahoo · 2026-11-16
- Eli Lilly Makes $1.5 Billion Move Beyond Weight-Loss DrugsYahoo · 2026-11-16
- Eli Lilly is trouncing Nvidia — and the weight-loss drug trade is beating AI againYahoo · 2026-11-16
Any AI summary is an interpretation of public news, not advice or a price target.